Product Information

AMITIZA 8 MCG CAPSULE is a brand product labeled by SpecGx LLC, priced at $6.4677 per EA under NDC 23635050860. Its NADAC has been published 93 times since Sep 18, 2024.

The High Outlier badge above means this manufacturer's average price in the lubiprostone market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

AMITIZA 8 MCG CAPSULE

lubiprostone
$6.4677per EA
High Outlier

Strength

8 ug/1

Manufacturer

SpecGx LLC

NDC

23635050860

Classification

Brand

Dosage Form

CAPSULE, GELATIN COATED

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

LUBIPROSTONE

Approval Type

New Drug (NDA)

FDA Application

NDA021908

On Market Since

4/1/2024

Pharmacological Classes

Chloride Channel Activator
Chloride Channel Activators

Price Statistics

The NADAC for AMITIZA 8 MCG CAPSULE has been published 93 times since Sep 18, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Current price$6.4677 per EA
All-time high$6.4677 (Jun 24, 2026)
All-time low$6.3960 (Sep 18, 2024)
52-week high$6.4677
52-week low$6.4372
Median price$6.4442
Average price$6.4418
Largest weekly change+0.2% (Mar 18, 2026)
Weeks tracked93
Tracking sinceSep 18, 2024

Price History

1W

0.0%

1M

0.0%

3M

+0.1%

6M

+0.2%

1Y

+0.4%

3Y

N/A

5Y

N/A

All

+1.1%

Generic Alternatives

The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 91% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 91%

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of AMITIZA 8 MCG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for AMITIZA 8 MCG CAPSULE, manufactured by SpecGx LLC, is $6.4677 per EA (NDC 23635050860), effective Jun 24, 2026.

How has the price of AMITIZA 8 MCG CAPSULE changed over time?

Over the history we have for it, the NADAC for AMITIZA 8 MCG CAPSULE has held within roughly two percent of its current level. It has been tracked across 93 weekly CMS publications since Sep 18, 2024.

What are the highest and lowest recorded NADAC prices for AMITIZA 8 MCG CAPSULE?

Since Sep 18, 2024, the NADAC for AMITIZA 8 MCG CAPSULE has ranged from a low of $6.3960 (Sep 18, 2024) to a high of $6.4677 (Jun 24, 2026), with a median of $6.4442 per EA.

Are there cheaper alternatives to AMITIZA 8 MCG CAPSULE?

Yes. 1 NADAC-published product shares the same active ingredient, strength, and dosage form. The lowest-priced option, LUBIPROSTONE 8 MCG CAPSULE, is $0.6039 per EA — about 91% below AMITIZA 8 MCG CAPSULE.

Who manufactures AMITIZA 8 MCG CAPSULE?

AMITIZA 8 MCG CAPSULE (NDC 23635050860) is labeled by SpecGx LLC, and CMS classifies it as a brand product.

Related Drugs

Same classification

No related drugs found.